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 1 
STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 Item 
No Recommendation 
 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1 
(b) Provide in the abstract an informative and balanced summary of what was done and 
what was found 
2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 4 
Objectives 3 State specific objectives, including any prespecified hypotheses 6 
Methods  
Study design 4 Present key elements of study design early in the paper 6 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
6 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. 
Describe methods of follow-up 
6 
(b) For matched studies, give matching criteria and number of exposed and unexposed - 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
7 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
6-8 
Bias 9 Describe any efforts to address potential sources of bias - 
Study size 10 Explain how the study size was arrived at 6 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
- 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding - 
(b) Describe any methods used to examine subgroups and interactions - 
(c) Explain how missing data were addressed - 
(d) If applicable, explain how loss to follow-up was addressed - 
(e) Describe any sensitivity analyses - 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, 
and analysed 
9 
(b) Give reasons for non-participation at each stage - 
(c) Consider use of a flow diagram - 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
15 
(b) Indicate number of participants with missing data for each variable of interest - 
(c) Summarise follow-up time (eg, average and total amount) - 
Outcome data 15* Report numbers of outcome events or summary measures over time - 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
- 
(b) Report category boundaries when continuous variables were categorized - 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
- 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 16 
 2 
analyses 
Discussion  
Key results 18 Summarise key results with reference to study objectives 11 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
12 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
12 
Generalisability 21 Discuss the generalisability (external validity) of the study results 14 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
14 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published 
examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web 
sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 
Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org. 
 
